Acrivon Therapeutics Inc. has announced that it will provide clinical updates in January 2026 on several ongoing studies and pipeline developments. The company will present updated interim clinical data from its ongoing registrational-intent Phase 2b study of ACR-368 (prexasertib), a selective CHK1/CHK2 inhibitor, in endometrial cancer, along with information on a recently initiated tumor biopsy-independent Phase 2b arm and the planned confirmatory Phase 3 trial. Initial clinical data from the ongoing Phase 1 study of ACR-2316, a WEE1/PKMYT1 inhibitor, will also be shared, including safety data, dosing regimen, and early clinical activity. Additionally, Acrivon will announce the nomination of a new preclinical development candidate for its AP3-driven cell cycle program. The results and updates will be presented in the future.